Los Alamos National Lab, Biomagnetics to develop and commercialize IOBS system

NewsGuard 100/100 Score

Biomagnetics Diagnostics Corp., (PINK SHEETS:BMGP) a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis, cholera and malaria detection, and other innovative technologies, today announced further details in next steps to be taken toward full commercialization of the Company's flagship Integrated Optical Biosensor (IOBS) diagnostic system. Biomagnetics is currently in collaboration with Los Alamos National Laboratory to develop the world's first integrated optical biosensor in a portable, handheld technology format designed to substantially lower unit costs and raise the detection levels of some of the world's most prevalent diseases.

Clayton Hardman, CEO of Biomagnetics Diagnostics Corp. stated, "We can now confirm that we are in the preliminary phase of design engineering as we work toward actual commercialization of the IOBS, a significant goal that represents the culmination of our efforts over the past year. After conferring with our design partner, Lathrope Engineering, we will be taking a twofold approach to best reach sales as soon as possible." Mr. Hardman continued, "Specifically, we will "ruggedize" the design of our bench top model for shipment and laboratory use, while concurrently miniaturizing the IOBS technology to fit within an easy-to-use hand held unit. We expect to receive a budget and schedule outlining the time-frame-to-completion for this project from Lathrope Engineering in the next two weeks."

Source:

 Biomagnetics Diagnostics Corp.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New malaria vaccine strain shows promise in preclinical trials